ClinicalTrials.gg
RecruitingNCT07377591Updated Jan 30, 2026

A Study of HDM2006 in Patients With Advanced Solid Tumor

A Phase 1 interventional study of HDM2006 in Advanced Solid Tumors, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Dec 2024, registered Jan 2026).
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2006 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. The subjects understand and voluntarily (or legally authorized guardian) sign a written form (ICF) approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).

    2. Males or females aged ≥ 18 years old. 3. In the dose escalation phase, subjects must have or cytologically confirmed advanced or solid tumors, who have experienced adequate standard treatment failure, intolerance to standard treatment, or lack of effective standard treatment.

    4. In the dose expansion phase, subjects must have histologically or cytologically confirmed advanced or metastatic specific types of tumors, who have experienced adequate standard treatment failure, intolerance to standard treatment, or lack of effective standard treatment. These include, but are not limited to, head and neck squamous cell carcinoma, renal cell carcinoma, cervix carcinoma, and other advanced solid tumors, as well as tumor types that showed efficacy signals (CR/PR) in the dose escalation phase.

    5. In the dose expansion phase, subjects are able to provide fresh or archival (within one year) tumor tissues at the time of screening and are willing to provide tumor tissue after administration of HDM2006 for baseline and post-treatment biomarker analysis.

    6. Performance Status (ECOG-PS) score of 0 or 1 .

    7. Expected survival time > 3 months. 8. According to the v1.1 (RECIST v1.1), subjects in phase 1a must have at least one evaluable lesion, and subjects in phase 1b must have at least one (a lesion located in areas previously treated with radiotherapy will not be considered a measurable lesion unless there is sufficient evidence to show clear imaging progression of the lesion after radiotherapy; biopsy lesions should be excluded for measurable lesions in subjects in phase 1b).

    9. The subject has good organ function as indicated by laboratory results at screening (no cytokine or other corrective medications are allowed within 14 days prior to laboratory tests at screening):Hematology: a) ≥ 1.5 × 10\^9/L (1500/mm3); b) count ≥ 100 × 10\^9/L (no platelet transfusion within 14 days prior to the investigation); c) ≥ 9.0 g/dL (no red blood cell transfusion within 30 days prior to the investigation); Liver: a) serum total ≤ 1.5 × ; b) and ALT ≤ 3 × ULN (≤ 5 × ULN for subjects with tumor liver metastasis); c) serum albumin ≥ 30 g/L (no albumin transfusion within 21 days prior to investigation); Kidney: blood creatinine ≤ 1.5 × ULN; or (CrCl) ≥ 50 mL/min (calculated by Cockcroft-Gault formula, see Appendix 4); Coagulation function: (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless the subject is receiving anticoagulant therapy, and the coagulation parameters [PT/INR and APTT] are within the expected range for anticoagulant therapy at screening).

    10. Women of (WOCBP) must be willing to use 2 adequate methods of or barrier contraception plus hormonal contraception from the time of signing ICF until 6 months after the last dose of study treatment to prevent pregnancy or abstain from heterosexual activity throughout the study; male subjects must agree to take adequate contraceptive measures from the first dose of study treatment until 6 months after the last dose of study treatment .

    11. Subject are willing and able to complete scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects who are concurrently participating in another clinical study, unless it is an observational (non-interventional) clinical study or they are in the survival follow-up period of an interventional study.

    2. Subjects with the following treatments:

    1. Subjects who have received major surgery within 4 weeks prior to the first dose, excluding minor surgery, such as appendicitis surgery, tissue acquisition for tumor , etc.;
    2. Subjects who have received bone marrow (equivalent to pelvic bone marrow area) or extensive radiotherapy within 28 days prior to the first dose; subjects who have received local radiotherapy (e.g., thoracic and rib radiotherapy) within 7 days prior to the first dose of the study drug;
    3. Subjects who have previously received HPK1 inhibitor treatment. 3. Subjects who have history of active within the past 2 years, with the exception of tumors in this study and cured local tumors, such as basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, cervix carcinoma in situ, breast cancer in situ, etc.

      4. Subjects who have not recovered (i.e., recover to ≤ Grade 1 or baseline) from related AEs (such as alopecia, ≤ Grade 2 sensory neuropathy, or other ≤ Grade 2 AEs that do not pose a safety risk as judged by the investigator) resulting from previous treatments or other anti-tumor therapies.

      5. Subjects with unstable : subjects with central nervous system complications requiring emergency neurosurgery (e.g., surgery) (excluding those who have completed surgery for more than 7 days and whose complications have resulted in ≤ Grade 1 side effects); 6. Subjects with epilepsy requiring treatment; subjects with a history of psychotropic drug abuse and unable to abstain or have mental disorders (those who have abstained must meet an observation period without withdrawal reactions for at least 2 weeks).

      7. Subjects with any of the following cardiovascular diseases/symptoms/signs:

    a) Mean (corrected QT interval, calculated by Fridericia's formula) at rest: male > 450 ms, female > 470 ms, with the mean QTc of triplicate measurements within ≥ 5 min (at least 1 min interval between two measurements, QT interval measurement should be from the beginning of the QRS complex to the end of the T wave); b) Any important abnormalities with in rhythm, conduction, or morphology of the ECG at rest, such as complete left bundle branch block, 2nd and 3rd degree heart block, PR interval > 250 ms, etc.; c) (LVEF) \< 50%; 8. Immunodeficiency diseases () and active hepatitis ( virus [HBV], virus [HCV]), excluding carriers with asymptomatic chronic HBV or HCV. Active HBV, HCV, and HIV positive infection is defined as: d) HBsAg is positive and HBV DNA is ≥ 2000 cps/mL (or 500 IU/mL); e) HCV antibody is positive and HCV RNA is higher than the (ULN) of the study site; f) HIV antibody is positive. 9. Diagnosed interstitial lung disease with or without symptoms, as well as conditions that may cause drug-induced lung toxicity or related pneumonia, or pulmonary symptoms that the investigator considers unsuitable for inclusion or high-risk factors that may lead to interstitial lung disease and are not suitable for inclusion.

    10. Subjects with other diseases that may affect the efficacy and safety of the study drug, including but not limited to:

    a) Active infection requiring antibiotic therapy within 14 days prior to the start of study treatment; b) Active disease or a history of autoimmune disease, including but not limited to inflammatory bowel disease, autoimmune hepatitis, Guillain-Barré syndrome, demyelinating disease, extensive dermatitis, immune-related interstitial pneumonia, or Grave's disease requiring drug medication; c) History of primary immunodeficiency; d) Active pulmonary tuberculosis; 11. A large amount or symptomatic moderate amount of pleural effusion, pericardial effusion, ascites at screening, and the symptoms are poorly controlled after treatment such as paracentesis and drainage.

    12. Clinically significant gastrointestinal abnormalities or diseases at screening, resulting in great difficulties in drug intake, transport, or absorption (such as dysphagia, uncontrollable nausea and vomiting), etc.

    13. History of solid organ transplant. 14. Known or suspected allergy to the study drug or its analogues. 15. Pregnant and lactating women. 16. The investigators consider that the subjects are not suitable to participate in this study (e.g., the treatment is not in the best interest of the subjects, the subjects have poor compliance, etc.).

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    HDM2006

    In dose escalation phase, participants will be administered escalating doses of HDM2006 at 50 mg QD, \~1000 mg QD, Oral administration within half an hour after a meal. In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2006, Oral administration within half an hour after a meal.

    Drug: HDM2006

Interventions

  • DrugHDM2006

    Oral administration within half an hour after a meal, QD

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)

    DLT will be determined by definition during the DLT observation period.

    Time frame: up to 21 days following first dose

  2. Incidence and severity of adverse events(for dose escalation phase)

    The safety profile of HDM2006 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

    Time frame: Until 30 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first

  3. Change from baseline in HPK1 expression in tumor tissues (dose expansion)

    HPK1 expression levels will be measured using Flow Cytometry. The unit of measure is percentage of positive cells.

    Time frame: through study completion, an average of 1 year

  4. Changes from baseline in pSLP-76 expression in tumor tissue (dose expansion)

    pSLP-76 expression levels will be measured using Flow Cytometry. The unit of measure is percentage of positive cells.

    Time frame: From baseline through study completion, an average of 1 year

  5. Recommended Phase 2 Dose (RP2D) (for dose expansion phase)

    The specific dose level of HDM2006 identified for use in the Phase 2 expansion phase

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Plasma concentration of HDM2006

    Plasma concentration of HDM2006

    Time frame: up to7 days following last dose

  2. Objective Response Rate (ORR)(for dose escalation phase)

    Objective response rate (ORR), which includes best response of complete response (CR) or partial response (PR) as assessed by the investigator.

    Time frame: through study completion, an average of 1 year

  3. Time to Response (TTR)

    TTR is defined as the interval from the start of study therapy to the first documentation of an objective response.

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  4. Progression free survival (PFS)

    PFS is defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  5. Duration of Response (DOR)

    DOR is defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to100 months

  6. Overall survival (OS)

    OS is defined as the interval from the start of study therapy to death from any cause.

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 30, 2026
StartActual
Dec 31, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Mar 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07377591
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Dec 31, 2024
Primary completion
Sep 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

LingLuo
Contact
cxyluoling@eastchinapharm.com
+86-18500798288

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion